Rocket Pharmaceuticals (RCKT) closed at $2.48 on November 11, 2026, up 1.2% from the previous close, on volume of 933,728 shares (30-day average 1,941,938).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
Cantor Fitzgerald Sticks to Its Buy Rating for Rocket Pharmaceuticals (RCKT)
TipRanks (Tue, 10-Nov 7:55 AM ET)
Rocket Pharmaceuticals to Participate in Chardan's 10th Annual Healthcare Conference
Business Wire (Thu, 15-Oct 7:00 AM ET)
Business Wire (Wed, 7-Oct 9:36 AM ET)
Business Wire (Tue, 6-Oct 4:12 PM ET)
Business Wire (Tue, 15-Sep 7:00 AM ET)
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
Business Wire (Thu, 3-Sep 7:00 AM ET)
Market Chameleon (Fri, 27-Mar 3:05 AM ET)
Market Chameleon (Fri, 27-Feb 5:34 AM ET)
Market Chameleon (Tue, 14-Oct 7:18 AM ET)
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Rocket Pharmaceuticals trades on the NASDAQ stock market under the symbol RCKT.
As of November 11, 2026, RCKT stock price climbed to $2.48 with 933,728 million shares trading.
RCKT has a beta of 2.50, meaning it tends to be more sensitive to market movements. RCKT has a correlation of 0.17 to the broad based SPY ETF.
RCKT has a market cap of $272.24 million. This is considered a Small Cap stock.
Last quarter Rocket Pharmaceuticals reported $0 in Revenue and -$.37 earnings per share. This fell short of revenue expectation by $-13 million and missed earnings estimates by -$.71.
In the last 3 years, RCKT traded as high as $32.53 and as low as $2.17.
The top ETF exchange traded funds that RCKT belongs to (by Net Assets): VTI, IWM, VXF, FESM, IWN.
RCKT has underperformed the market in the last year with a return of -21.3%, while the SPY ETF gained +12.6%. In the last 3 month period, RCKT fell short of the market, returning -31.9%, while SPY returned -1.5%. However, in the most recent 2 weeks RCKT has outperformed the stock market by returning +1.2%, while SPY returned -1.3%.
RCKT support price is $2.33 and resistance is $2.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RCKT shares will trade within this expected range on the day.
